This database contains 137 studies, archived under the term: "Conclusions"
Click here to filter this large number of results.
Role of a multidisciplinary program in improving outcomes in cognitively impaired heart failure older patients
Del Sindaco, Donatella,
Pulignano, Giovanni,
Di Lenarda, Andrea,
Tarantini, Luigi,
Cioffi, Giovanni,
Tolone, Stefano,
Tinti, Maria Denitza,
Monzo, Luca,
Barbati, Giulia,
Minardi, Giovanni
Background: Cognitive impairment (CI) frequently complicates Heart failure (HF) and is associated with increased mortality and morbidity. Previous studies reported that nurse-lead home-based multidisciplinary program (MP) may not improve the prognosis of this high-risk group. In the present study, we analysed the relative effectiveness of an integrated hospital-based MP in patients with cognitive impairment.; Methods: […]
Detecting MCI and dementia in primary care: effectiveness of the MMS, the FAQ and the IQCODE corrected
Cruz-Orduña, Isabel,
Bellón, José M.,
Torrero, Pedro,
Aparicio, Esperanza,
Sanz, Ana,
Mula, Nieves,
Marzana, Garbiñe,
Begué, Concepción,
Cabezón, Dionisio,
Olazarán, Javier
Objectives: To study the yield of three instruments for detection of patients with cognitive impairment in primary care. To investigate whether combining tests is better for detecting impairment than applying them separately.; Methods: Seven primary care physicians (PCP) systematically recruited individuals aged over 49 years with a complaint or suspicion of cognitive impairment. The tests […]
Safety and pharmacology of ponezumab (PF-04360365) after a single 10-minute intravenous infusion in subjects with mild to moderate Alzheimer disease
Burstein, Aaron H,
Zhao, Qinying,
Ross, Joel,
Styren, Scot,
Landen, Jaren W.,
Ma, Wendy W.,
McCush, Fred,
Alvey, Christine,
Kupiec, James W.,
Bednar, Martin M.
Objective: Ponezumab (PF-04360365) is a humanized anti-amyloid beta (Aβ) monoclonal antibody designed for treatment of Alzheimer disease (AD). A single 2-hour intravenous infusion of 0.1 to 10 mg/kg was previously shown to be safe and well tolerated in subjects with mild to moderate AD, with measurable effects on plasma and cerebrospinal fluid Aβ. This phase […]
Developing an educational intervention on dementia diagnosis and management in primary care for the EVIDEM-ED trial
Iliffe, Steve,
Koch, Tamar,
Jain, Priya,
Lefford, Frances,
Wong, Geoffrey,
Warner, Alex,
Wilcock, Jane
Background: Dementia syndromes are under-diagnosed and under-treated in primary care. Earlier recognition of and response to dementia syndrome is likely to enhance the quality of life of people with dementia, but general practitioners consistently report limited skills and confidence in diagnosis and management of this condition. Changing clinical practice is difficult, and the challenge for […]
Study protocol for a randomized controlled trial of humor therapy in residential care: the Sydney Multisite Intervention of LaughterBosses and ElderClowns (SMILE)
Goodenough, Belinda,
Low, Lee-Fay,
Casey, Anne-Nicole,
Chenoweth, Lynn,
Fleming, Richard,
Spitzer, Peter,
Bell, Jean-Paul,
Brodaty, Henry
Background: Humor therapy is a non-pharmacological intervention with potential to improve mood and quality of life for institutionalized older persons, including those with dementia. The primary aims of the Sydney Multisite Intervention of LaughterBosses and ElderClowns (SMILE) are to examine the effects of humor therapy on residents’ mood, quality of life, social engagement, and agitation.; […]
Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease
Blennow, Kaj,
Zetterberg, Henrik,
Rinne, Juha O.,
Salloway, Stephen,
Wei, Jenny,
Black, Ronald,
Grundman, Michael,
Liu, Enchi
Background: Given the slow and variable clinical course of Alzheimer disease, very large and extended clinical trials are needed to identify a beneficial clinical effect of disease-modifying treatments. Therefore, biomarkers are essential to prove that an anti-β-amyloid (Aβ) drug candidate affects both Aβ metabolism and plaque load as well as downstream pathogenic mechanisms.; Objective: To […]
Physical therapy in Huntington’s disease–toward objective assessments?
Bohlen, S.,
Ekwall, C.,
Hellström, K.,
Vesterlin, H.,
Björnefur, M.,
Wiklund, L.,
Reilmann, R.
Background and Purpose: Physical therapy is recommended for the treatment of Huntington’s disease, but reliable studies investigating its efficacy are almost non-existent. This may in part be due to the lack of suitable outcome measures. Therefore, we investigated the applicability of novel quantitative and objective assessments of motor dysfunction in the evaluation of physical therapy […]
Leisure activities alleviate depressive symptoms in nursing home residents with very mild or mild dementia
Objectives: : To examine whether leisure activities can alleviate depressive symptoms among nursing home residents with very mild to mild dementia.; Methods: : A cluster-randomized open-label controlled design. Thirty-six residents with at least moderate depressive symptoms were randomized by home into three conditions-mahjong (a.k.a. mah-jongg), tai chi, and handicrafts (placebo). Activities were conducted three times […]